We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals

340 hedge funds and large institutions have $1.33B invested in Recursion Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 124 increasing their positions, 86 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 86

37% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 52

36% more call options, than puts

Call options by funds: $40.1M | Put options by funds: $29.5M

21% more capital inflows, than outflows

Capital inflows: $249M | Capital outflows: $206M

4% more funds holding

Funds holding: 327 → 340 (+13)

14.07% less ownership

Funds ownership: 77.11% → 63.04% (-14%)

50% less funds holding in top 10

Funds holding in top 10: 8 → 4 (-4)

Holders
340
Holders Change
+13
Holders Change %
+3.98%
% of All Funds
4.09%
Holding in Top 10
4
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
71
Increased
124
Reduced
86
Closed
52
Calls
$40.1​M
Puts
$29.5​M
Net Calls
+$10.6​M
Net Calls Change
-⁠$11.1​M

RXRX Hedge Fund Activity: Q4 2025 in Review

340 of the 8,319 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2025, worth a combined $1.33B — down 18% from $1.61B a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new RXRX positions and 52 closed out — a net gain of 19 holders — while 124 added to existing stakes and 86 trimmed.

The largest buyer was Vanguard Group, adding an estimated $36.7M. The largest seller was Mubadala Investment Company, exiting entirely with an estimated $63.4M sold.

  • 340 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2025, up from 327 in Q3 2025.
  • Funds reported $1.33B of Recursion Pharmaceuticals stock for Q4 2025, down 18% quarter-over-quarter.
  • 71 funds opened new Recursion Pharmaceuticals positions in Q4 2025 and 52 closed out, a net change of +19 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2025 was Vanguard Group, an estimated $36.7M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2025 was Mubadala Investment Company, an estimated $63.4M sold.

Based on aggregated 13F filings for Q4 2025.